Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Quick Look at What’s Ahead for Atlas Pipeline Partners, L.P. (APL)

Page 1 of 2

Natural gas gathering and processing company Atlas Pipeline Partners, L.P. (NYSE:APL) is out with its 2013 guidance. Not only did the company update the market on its growth plans for 2013, but it also hinted at what where its distributions will likely end up. Let’s take a closer look at the importance of each for investors.

Atlas Pipeline Partners, L.P. (NYSE:APL)Capital allocation
Atlas is planning to spend about $350 million over the next year on growth projects. That’s a pretty big chunk of change for a company with a $2 billion market cap. That capital will be spent in building out its gathering infrastructure. Atlas also recently announced that it was accelerating the timing of the second half of its WestTx expansion into 2013. This is in addition to completing the first half of the expansion in the second quarter of this year. Visible and stable growth is what midstream investors look for and Atlas has both.

One key area of growth for Atlas is in the promising Mississippi Lime. Earlier this year the company signed a new percent-of-proceeds contract with SandRidge Energy Inc. (NYSE:SD) to compliment a fixed-fee gathering agreement. SandRidge is the largest producer in the play and is now almost solely focused on growing in the play. As it does, Atlas should continue to benefit from its early relationship with SandRidge as it likely will mean additional growth opportunities will flow its way.

All of this is part of a broad capital expansion and acquisition plan that’s seen the company allocate $1.2 billion in capital over the past few years. More than half of that capital was spent to acquire Cardinal Midstream in a more than $600 million deal. The system, now renamed Akroma, is going to see additional capital headed its way to fund expansion opportunities. This capital is being spent for one purpose: to place assets into the service of Atlas investors in order to start generating revenue, which will increase the company’s distributable cash flow.

Income distribution
Atlas is currently dishing out $0.58 a unit to its investors which equates to a near 7% distribution. Looking out over the past year you’ll see that it has handed out $2.27 per unit which is a 16% increase from 2011. According to management, there’s more on the way as its growth and acquisition capital starts bearing fruit. Atlas is forecasting that its 2013 distributions will come in between $2.50 and $2.60 per unit. That’s a nice pay raise if you can get it.

The midstream MLP space seems to be a tale of two distributions, those that grow and those that don’t. There are those MLP’s like Enterprise Products Partners L.P. (NYSE:EPD) that have given investors a distribution raise each quarter. In fact, Enterprise investors have been given a pay raise for 34 consecutive quarters. Other operators, like Energy Transfer Partners LP (NYSE:ETP), haven’t given investors a raise in 19 straight quarters. That’s almost five years for those of you scoring at home.

Take a look at the following charts and you’ll see what a rising distribution means for investors:

APL Dividend Chart

APL Dividend data by YCharts

APL Chart

APL data by YCharts

Atlas’ growth has enabled the company to increase its payout, which has rewarded investors with both income and more valuable units. While the pace of that growth is slowing, it is still headed higher. That’s a good thing for investors, as long as the company can keep it up.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!